Literature DB >> 14981762

Differential display RT-PCR analysis of ECV304 endothelial-like cells infected with dengue virus type 2 reveals messenger RNA expression profiles of multiple human genes involved in known and novel roles.

Kingsley J L Liew1, Vincent T K Chow.   

Abstract

Differential display (DD)-RT-PCR was employed to analyze mRNAs from ECV304 human endothelial-like cells undergoing apoptosis following infection with the virulent New Guinea C strain of dengue virus type 2 in order to elucidate the cellular gene responses to dengue viral infection at the transcriptional level. We isolated, sequenced, and identified 203 differentially expressed and overlapping cDNA fragments, all of which were of human origin except 1 that was of viral origin. Out of these, 78 were individual distinct clones comprising 46 and 32 expressed sequence tags (ESTs) that exhibited upregulated and downregulated trends, respectively. Of the 78 differentially expressed mRNAs, 16 did not match any characterized genes or ESTs. The remaining 62 mRNAs modified by dengue virus infection matched known genes, including those encoding components of the cell cycle (Anillin, CDC27), cytoskeleton (epsilon-tubulin), signal transduction (OPHN1, PPP2R2A, TIRAP), protein translation and modification (EIF3S10, IF2, TMEM1), transcriptional regulation (alpha-NAC, C20orf104, EGR1, ELP2), apoptotic cell death (RICK), membrane (BPAG1), and mitochondrial-related proteins. Semiquantitative RT-PCR and real-time RT-PCR authenticated further the altered expression patterns of selected genes of interest. These data demonstrate the feasibility of mRNA DD in providing insights into the complex responses of the transcriptional machinery of permissive and apoptotic human endothelial-like cells in the pathogenesis of dengue and/or its complications induced by the virulent dengue virus type 2. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981762     DOI: 10.1002/jmv.20034

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Productive dengue virus infection of human endothelial cells is directed by heparan sulfate-containing proteoglycan receptors.

Authors:  Nadine Dalrymple; Erich R Mackow
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

2.  MCP-1 antibody treatment enhances damage and impedes repair of the alveolar epithelium in influenza pneumonitis.

Authors:  T Narasaraju; H H Ng; M C Phoon; Vincent T K Chow
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-17       Impact factor: 6.914

3.  Identification of cellular proteome modifications in response to West Nile virus infection.

Authors:  Boris Pastorino; Elodie Boucomont-Chapeaublanc; Christophe N Peyrefitte; Maya Belghazi; Thierry Fusaï; Christophe Rogier; Hugues J Tolou; Lionel Almeras
Journal:  Mol Cell Proteomics       Date:  2009-04-24       Impact factor: 5.911

4.  Enhancement by tumor necrosis factor alpha of dengue virus-induced endothelial cell production of reactive nitrogen and oxygen species is key to hemorrhage development.

Authors:  Yu-Ting Yen; Hsuen-Chin Chen; Hseun-Chin Chen; Yang-Ding Lin; Chi-Chang Shieh; Betty A Wu-Hsieh
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

5.  Microarray and real-time RT-PCR analyses of differential human gene expression patterns induced by severe acute respiratory syndrome (SARS) coronavirus infection of Vero cells.

Authors:  W F Leong; H C Tan; E E Ooi; D R Koh; Vincent T K Chow
Journal:  Microbes Infect       Date:  2005-01-22       Impact factor: 2.700

6.  Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal differential cellular gene expression in response to enterovirus 71 infection.

Authors:  Wai Fook Leong; Vincent T K Chow
Journal:  Cell Microbiol       Date:  2006-04       Impact factor: 3.715

Review 7.  Recent advances in DENV receptors.

Authors:  Shuyu Fang; Yanhua Wu; Na Wu; Jing Zhang; Jing An
Journal:  ScientificWorldJournal       Date:  2013-04-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.